Minter Ellison represents pharmaceutical companies in patent infringement case
In a unanimous five-judge Full Federal Court decision handed down on 12 August, AstraZeneca has once again failed to prevent generic companies from selling competing generic versions of its Crestor (rosuvastatin) cholesterol drug. Minter Ellison represented Watson and Ascent in this matter.
Sign in or Register to continue reading this article
It's quick, easy and free!
Why register to The Lawyer
More relevant to you
News from Minter Ellison
News from The Lawyer
Briefings from Minter Ellison
This page provides a link to all the relevant discussion papers.
Despite their prevalence, there has been some uncertainty in relation to the income tax treatment of earnout arrangements.